Elsevier has a pharmacy management software called Clinical Pharmacology. It is designed to help pharmacists, physicians, nurses, and other clinicians find relevant knowledge for confident drug counseling, well-informed medication decisions, and optimal patient safety. In this article, we cover Elsevier reviews and pricing. Ready to get started? Get a free trial.
Elsevier pricing is not readily available on its website, but according to a third-party source, a yearly subscription costs $199. There is also an extra charge of $99 for add-on modules such as the Drug IDentifier/NDC Search, $99 for the IV Compatibility, $119 for the OnFormulary, and $39 for the Global Drug Name Database (GDND).
Interested users may contact Elsevier to get a quote for their customized plan.
Ready to try Elsevier? Get a free trial.
Top Elsevier Alternative 2019
Summary of Elsevier Reviews
As of the date this article was written (March 26, 2019), there are no Elsevier reviews available online. If you are a past or current Elsevier customer, leave a review to help other business owners who are deciding whether or not to use the software.
Check out the list below of some of Elsevier’s features:
- Immediate access to important updates
- Superior quality content
- Top speed-to-answer
- All-inclusive, enterprise-wide solution
- Flexible delivery options
- Promote efficiency and organizational compliance
- Drive innovative pharmaceutical research
- And more
How does Elsevier determine the eligibility criteria for customers?
The criteria that determine which customers are eligible for migration to the new Title-by-Title option in 2011 have been set in such a way that the set of eligible customers is a representative sample of its academic, government, and Title-by-Title customer base. It also considers whether the scale is small enough to ensure that it can manage the migration and test the new concepts in a controlled manner, allowing for adequate interaction and response.
How can I subscribe to journals that are not included in the Title-by-Title option?
For journals that are not in the scope of the Title-by-Title option (e.g., Masson & Doyma journals and New Scientist), the existing pricing models will continue to apply. A separate agreement may be required for subscriptions to these journals.